These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38196615)

  • 1. Fibroblast Growth Factor (FGF) 23 and FGF Receptor 4 promote cardiac metabolic remodeling in chronic kidney disease.
    Fuchs MA; Burke EJ; Latic N; Murray S; Li H; Sparks M; Abraham D; Zhang H; Rosenberg P; Hänzelmann S; Hausmann F; Huber T; Erben R; Fisher-Wellman K; Bursac N; Wolf M; Grabner A
    Res Sq; 2023 Dec; ():. PubMed ID: 38196615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.
    Grabner A; Schramm K; Silswal N; Hendrix M; Yanucil C; Czaya B; Singh S; Wolf M; Hermann S; Stypmann J; Di Marco GS; Brand M; Wacker MJ; Faul C
    Sci Rep; 2017 May; 7(1):1993. PubMed ID: 28512310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypericin Alleviates Chronic Kidney Disease-induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4 Signaling Pathway.
    Liu M; Cheng L; Ye Q; Liu H; Shu C; Gao H; Liu X; Zhang X; Chen G
    J Cardiovasc Pharmacol; 2024 Jun; 83(6):588-601. PubMed ID: 38547517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
    Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
    Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
    Grabner A; Amaral AP; Schramm K; Singh S; Sloan A; Yanucil C; Li J; Shehadeh LA; Hare JM; David V; Martin A; Fornoni A; Di Marco GS; Kentrup D; Reuter S; Mayer AB; Pavenstädt H; Stypmann J; Kuhn C; Hille S; Frey N; Leifheit-Nestler M; Richter B; Haffner D; Abraham R; Bange J; Sperl B; Ullrich A; Brand M; Wolf M; Faul C
    Cell Metab; 2015 Dec; 22(6):1020-32. PubMed ID: 26437603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Fibroblast Growth Factor 23 Excess Does Not Induce Left Ventricular Hypertrophy in Healthy Mice.
    Leifheit-Nestler M; Wagner MA; Richter B; Piepert C; Eitner F; Böckmann I; Vogt I; Grund A; Hille SS; Foinquinos A; Zimmer K; Thum T; Müller OJ; Haffner D
    Front Cell Dev Biol; 2021; 9():745892. PubMed ID: 34778257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner.
    Graves JM; Vallejo JA; Hamill CS; Wang D; Ahuja R; Patel S; Faul C; Wacker MJ
    Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2283-H2294. PubMed ID: 33929896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF23 induces left ventricular hypertrophy.
    Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
    J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice.
    Han X; Cai C; Xiao Z; Quarles LD
    J Mol Cell Cardiol; 2020 Jan; 138():66-74. PubMed ID: 31758962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23.
    Yan L; Bowman MA
    Inflamm Cell Signal; 2014; 1(5):. PubMed ID: 26082935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR4 does not contribute to progression of chronic kidney disease.
    Taylor A; Yanucil C; Musgrove J; Shi M; Ide S; Souma T; Faul C; Wolf M; Grabner A
    Sci Rep; 2019 Oct; 9(1):14023. PubMed ID: 31575945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
    Di Marco GS; Reuter S; Kentrup D; Grabner A; Amaral AP; Fobker M; Stypmann J; Pavenstädt H; Wolf M; Faul C; Brand M
    Nephrol Dial Transplant; 2014 Nov; 29(11):2028-35. PubMed ID: 24875663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoxyl sulfate induces left ventricular hypertrophy
    Kishimoto H; Nakano T; Torisu K; Tokumoto M; Uchida Y; Yamada S; Taniguchi M; Kitazono T
    Front Cardiovasc Med; 2023; 10():990422. PubMed ID: 36895836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease.
    Watanabe K; Fujii H; Okamoto K; Kono K; Goto S; Nishi S
    Front Endocrinol (Lausanne); 2023; 14():1276664. PubMed ID: 38174329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic background influences cardiac phenotype in murine chronic kidney disease.
    Neuburg S; Dussold C; Gerber C; Wang X; Francis C; Qi L; David V; Wolf M; Martin A
    Nephrol Dial Transplant; 2018 Jul; 33(7):1129-1137. PubMed ID: 29309658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease.
    Yanucil C; Kentrup D; Campos I; Czaya B; Heitman K; Westbrook D; Osis G; Grabner A; Wende AR; Vallejo J; Wacker MJ; Navarro-Garcia JA; Ruiz-Hurtado G; Zhang F; Song Y; Linhardt RJ; White K; Kapiloff MS; Faul C
    Kidney Int; 2022 Aug; 102(2):261-279. PubMed ID: 35513125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac actions of fibroblast growth factor 23.
    Faul C
    Bone; 2017 Jul; 100():69-79. PubMed ID: 27725315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR4 and Klotho Polymorphisms Are Not Associated with Cardiovascular Outcomes in Chronic Kidney Disease.
    Sellier AB; Seiler-Mußler S; Emrich IE; Böhm M; Fliser D; Zawada AM; Heine GH
    Am J Nephrol; 2021; 52(10-11):808-816. PubMed ID: 34673637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and indirect effects of fibroblast growth factor 23 on the heart.
    Nakano T; Kishimoto H; Tokumoto M
    Front Endocrinol (Lausanne); 2023; 14():1059179. PubMed ID: 36909314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.